Atrium Therapeutics, Inc.
No SEC Form 4 filings for $RNA in the last 30 days.
See all $RNA insider activity →Atrium Therapeutics (RNA) reported Q2 2026 results, highlighting FDA clearance for ATR 1072 and a $15M milestone payment from Bristol Myers Squibb. The company has $263.9M in cash, enough to fund operations through mid-2028. However, expenses outpaced revenue, with $25.6M in costs against $3M in collaboration revenue. Clinical trials are in early stages, with data expected in H2 2027.
Atrium Therapeutics (RNA) received a $15M milestone payment from Bristol-Myers Squibb (BMY) for delivering an RNA compound. The deal could yield up to $2.175B in milestones. BMY reported Q2 2026 revenue of $12.97B, raising its full-year guidance. Atrium remains unprofitable but has $264M in cash. Investors should watch for clinical readouts and regulatory progress.
Atrium Therapeutics (RNA) granted inducement awards to a new non-executive hire, including options for 11,000 shares and restricted stock units for 5,500 shares. The awards vest over time, subject to continued employment. The company focuses on RNA therapeutics for heart diseases and recently cleared an IND application for its first clinical trial.
Over the past 7 days, alphai's AI scored 1 news story mentioning RNA (Atrium Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RNA coverage spans financial news, technology and corporate actions.
Positive regulatory milestone may support short‑term price upside; long‑term impact depends on trial outcomes.
Positive cash infusion improves runway and validates platform.
The grant is a routine equity compensation event, likely modestly dilutive but not material to price.
IND clearance and trial initiation are near-term de-risking catalysts for Atrium’s first precision cardiology program, with additional cash impact from a BMS milestone.
Regulatory clearance and trial activation are near-term de-risking catalysts for Atrium’s first clinic-stage precision cardiology program.
alphai scores every news story that mentions RNA with an AI model for sentiment and relevance, and aggregates insider trades from Atrium Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Atrium Therapeutics (RNA) reported Q2 2026 results, highlighting FDA clearance for ATR 1072 and a $15M milestone payment from Bristol Myers Squibb. The company has $263.9M in cash, enough to fund operations through mid-2028. However, expenses outpaced revenue, with $25.6M in costs against $3M in collaboration revenue. Clinical trials are in early stages, with data expected in H2 2027.
2 min readAtrium Therapeutics (RNA) received a $15M milestone payment from Bristol-Myers Squibb (BMY) for delivering an RNA compound. The deal could yield up to $2.175B in milestones. BMY reported Q2 2026 revenue of $12.97B, raising its full-year guidance. Atrium remains unprofitable but has $264M in cash. Investors should watch for clinical readouts and regulatory progress.
2 min readAtrium Therapeutics (RNA) granted inducement awards to a new non-executive hire, including options for 11,000 shares and restricted stock units for 5,500 shares. The awards vest over time, subject to continued employment. The company focuses on RNA therapeutics for heart diseases and recently cleared an IND application for its first clinical trial.
1 min readAtrium Therapeutics (Nasdaq: RNA) reported Q2 2026 results for the quarter ended June 30. FDA cleared its IND for ATR 1072 and it launched the Corventis Phase 1/2 trial for PRKAG2 syndrome. Atrium also received a $15 million second milestone payment from Bristol Myers Squibb. Q2 collaboration revenue was $3.0M, R&D $15.3M, G&A $10.3M, cash $263.9M.
6 min readAtrium Therapeutics, Inc. (RNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb — SAN D
4 min read24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
4 min readAtrium Therapeutics (RNA) said the FDA cleared its IND for ATR 1072 to start its first precision cardiology program for PRKAG2 syndrome, a rare genetic cardiomyopathy with no approved root-cause therapies. ATR 1072 uses siRNA to silence mutant PRKAG2 mRNA and normalize AMPK activity. A Corventis Phase 1/2 trial will enroll ~37 patients, with first enrollment by end-2026 and proof-of-concept expected in 2H 2027.
3 min readCantor Fitzgerald began coverage of Avidity Biosciences (NASDAQ: RNA) with an “overweight” rating and a $25.00 price target, implying 100.32% upside from the stock’s level. Other analysts cited include Wells Fargo (overweight) and Leerink (outperform), while consensus remains “Hold” with an average target of $66.81. The stock opened at $12.48; on May 14 it reported Q1 EPS of -$0.97 and revenue of $19.64M.
4 min readAvidity Biosciences announced the expansion of its RNA therapeutic discovery pipeline, adding new research and development candidates in skeletal muscle and cardiology. The company is leveraging its proprietary AOC platform to target previously untreatable diseases and continues to advance three rare disease programs in Phase 1/2 clinical development for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Avidity also maintains collaborations with Eli Lilly and Company and MyoKardia to further explore its AOC platform's potential.
3 min readAvidity Biosciences Inc. reached an all-time high of $72.70, marking a 141.25% increase over the past year, driven by investor confidence in its RNA-based therapies. The company also announced a Managed Access Program for delpacibart zotadirsen for Duchenne muscular dystrophy patients and will be acquired by Novartis for approximately $12 billion ($72 per share). Following the acquisition news, analysts at Chardan Capital Markets and TD Cowen downgraded the stock and adjusted their price targets.
4 min read
